Havel J J, Li Z, Cheng D, Peng J, Fu H
1] Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA [2] Graduate Program in Molecular and Systems Pharmacology, Emory University, Atlanta, GA, USA.
Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA.
Oncogene. 2015 Mar 19;34(12):1487-98. doi: 10.1038/onc.2014.91. Epub 2014 Apr 7.
The ribosomal protein (RP)-HDM2-p53 pathway has been shown to have key roles in oncogene-induced apoptosis and senescence, but the mechanism regulating this pathway remains elusive. The proline-rich Akt substrate of 40 kDa (PRAS40) has recently been identified as a binding partner and inhibitor of the mechanistic (formerly referred to as mammalian) target of rapamycin complex 1 (mTORC1). Although other inhibitors of mTORC1 are known tumor suppressors, PRAS40 promotes cell survival and tumorigenesis. Here we demonstrate that Akt- and mTORC1-mediated phosphorylation of PRAS40 at T246 and S221, respectively, promotes nuclear-specific association of PRAS40 with ribosomal protein L11 (RPL11). Importantly, silencing of PRAS40 induces upregulation of p53 in a manner dependent on RPL11. This effect is rescued by wild-type PRAS40, but not by the RPL11-binding-null PRAS40T246A mutant. We found that PRAS40 negatively regulates the RPL11-HDM2-p53 nucleolar stress response pathway and suppresses induction of p53-mediated cellular senescence. This work identifies nuclear PRAS40 as a dual-input signaling checkpoint that links cell growth and proliferation to inhibition of cellular senescence. These findings may help to explain the protumorigenic effect of PRAS40 and identify the PRAS40-RPL11 complex as a promising target for p53-restorative anticancer drug discovery.
核糖体蛋白(RP)-HDM2-p53通路已被证明在癌基因诱导的细胞凋亡和衰老中起关键作用,但调节该通路的机制仍不清楚。富含脯氨酸的40 kDa Akt底物(PRAS40)最近被鉴定为雷帕霉素复合物1(mTORC1)机制性(以前称为哺乳动物)靶点的结合伴侣和抑制剂。尽管mTORC1的其他抑制剂是已知的肿瘤抑制因子,但PRAS40促进细胞存活和肿瘤发生。在这里,我们证明Akt和mTORC1分别介导的PRAS40在T246和S221位点的磷酸化促进了PRAS40与核糖体蛋白L11(RPL11)的核特异性结合。重要的是,PRAS40的沉默以依赖RPL11的方式诱导p53上调。野生型PRAS40可挽救这种效应,但RPL11结合缺失的PRAS40T246A突变体则不能。我们发现PRAS40负向调节RPL11-HDM2-p53核仁应激反应通路,并抑制p53介导的细胞衰老诱导。这项工作将核PRAS40鉴定为一个双输入信号检查点,它将细胞生长和增殖与细胞衰老的抑制联系起来。这些发现可能有助于解释PRAS40的促肿瘤作用,并将PRAS40-RPL11复合物鉴定为恢复p53功能的抗癌药物发现的一个有希望的靶点。